CD79A and neoplasm: However, a significantly increased activity of anti-CD20 IgA2 was reported in CD89 transgenic mice in comparison to wild-type mice (165), highlighting the potential for tumor cytotoxicity downstream of IgA interaction with cognate receptor-expressing effector cells in vivo.